The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Does capecitabine plus cisplatin (XP) give advanced or recurrent gastric cancer (AGC) patients higher early tumor shrinkage (ETS) rate than S1 plus cisplatin (SP) with safety?
 
Naotoshi Sugimoto
Research Funding - Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly; Sanofi; Taiho Pharmaceutical
 
Tetsuhiro Yoshinami
No Relationships to Disclose
 
Sachiko Yamamoto
No Relationships to Disclose
 
Toshinari Yagi
No Relationships to Disclose
 
Fumio Imamura
No Relationships to Disclose